Is a spin-off of one of its business segments in the cards for Johnson & Johnson this year? Stranger things have happened before.
Will AbbVie face a rocky road in the new year because of these significant risks?
It was a banner year for companies developing drugs associated with compounds found in marijuana.
AstraZeneca's shares continued their downward spiral last month, falling by more than 8%.
Here's how Axim Biotechnologies, CoLucid Pharmaceuticals, Corbus Pharmaceuticals, Exelixis, and Tesaro outperformed their peers this year, and their outlooks for 2017
If you're looking for stocks that combine solid dividends and growth potential, drugmakers Bristol-Myers Squibb, AbbVie, and Lilly might be right for you.
AbbVie shares sank Friday on disappointing Q3 results. Here's what management had to say.
Here's what you need to know about what Amgen's management said in the biotech's Q3 earnings call.
Among medical mutual funds, the Vanguard Health Care Fund stands out for performance, low expenses, and its managers' buy-and-hold philosophy. But don't buy it just for the yield -- its high dividend is an illusion.
Looking for Big Pharma bargains? Mallinckrodt, Bayer, and Bristol-Myers Squibb might be right up your alley.